2-氯-1-(6,7-二甲氧基-1-苯基-3,4-二氢-1H-异喹啉-2-基)-乙酮 | 66040-35-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 2-氯-1-(6,7-二甲氧基-1-苯基-3,4-二氢-1H-异喹啉-2-基)-乙酮
• 英文名称: 2-chloroacetyl-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-isoquinoline
• 英文别名: N-(2-chloroacetyl)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline；2-Chloro-1-(6,7-dimethoxy-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone；2-chloro-1-(6,7-dimethoxy-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)ethanone
• CAS: 66040-35-5
• 化学式: C₁₉H₂₀ClNO₃
• mdl: MFCD04621542
• 分子量: 345.826
• InChiKey: UTYPGSLYQSEHGZ-UHFFFAOYSA-N

物化性质

• 熔点：
  220-221 °C
• 沸点：
  506.5±50.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.315
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  2-氯-1-(6,7-二甲氧基-1-苯基-3,4-二氢-1H-异喹啉-2-基)-乙酮 、 二乙胺 在 potassium carbonate 作用下， 以 甲苯 为溶剂， 反应 1.5h， 以45%的产率得到2-(diethylaminoacetyl)-6,7-dimethoxy-1-phenyl-1,2,3,4-terahydroisoquinoline
  参考文献：
  名称：

  Novel Potent Anticonvulsant Agent Containing a Tetrahydroisoquinoline Skeleton

  摘要：

  In our studies on the development of new anticonvulsants, we planned the synthesis of N-substituted 1,2,3,4-tetrahydroisoquinolines to explore the structure-activity relationships. All derivatives were evaluated against audiogenic seizures in DBA/2 mice, and the 1-(4'-bromophenyl)-6,7-dimethoxy-2-(piperidin-1-ylacetyl)derivative (26) showed the highest activity with a potency comparable to that of talampanel, the only noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist in clinical trials as an anticonvulsant agent. Electrophysiological experiments indicated that 26 acts as noncompetitive AMPA receptor modulator.

  DOI：

  10.1021/jm060411b
• 作为产物：
  描述：

  6,7-二甲氧基-1-苯基-1,2,3,4-四氢异喹啉 、 氯乙酰氯 以 氯仿 为溶剂， 反应 1.5h， 生成 2-氯-1-(6,7-二甲氧基-1-苯基-3,4-二氢-1H-异喹啉-2-基)-乙酮
  参考文献：
  名称：

  Novel Potent Anticonvulsant Agent Containing a Tetrahydroisoquinoline Skeleton

  摘要：

  In our studies on the development of new anticonvulsants, we planned the synthesis of N-substituted 1,2,3,4-tetrahydroisoquinolines to explore the structure-activity relationships. All derivatives were evaluated against audiogenic seizures in DBA/2 mice, and the 1-(4'-bromophenyl)-6,7-dimethoxy-2-(piperidin-1-ylacetyl)derivative (26) showed the highest activity with a potency comparable to that of talampanel, the only noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist in clinical trials as an anticonvulsant agent. Electrophysiological experiments indicated that 26 acts as noncompetitive AMPA receptor modulator.

  DOI：

  10.1021/jm060411b

文献信息

• N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme
  申请人：Schering Corporation

  公开号：US05124337A1

  公开（公告）日：1992-06-23

  N-acyltetrahydroisoquinolines including novel compounds of the formula ##STR1## wherein R.sup.1 is a C10-C25 alkyl chain; a substituted C10-C25 alkyl chain; an interrupted C10-C25 alkyl chain; a substituted interrupted C10-C25 alkyl chain; diphenylamino; di-(R.sup.2 -substituted phenyl)amino; di-(heteroaryl)amino; di-R.sup.2 -substituted heteroary)amino; diphenylmethyl; or di-(R.sup.2 -substituted phenyl)methyl; R.sup.2 is hydroxy, lower alkyl, lower alkoxy, halogeno, amino, lower alkylamino or di-(lower alkyl)amino; R.sup.3, R.sup.4 and R.sup.5 are independently H or --(CH.sub.2 .sub.n --Ar; Ar is phenyl, R.sup.2 -substituted phenyl, heteroaryl or R.sup.2 -substituted heteroaryl; n=0,1 or 2; m=0,1 or 2; or a pharmaceutically acceptable salt thereof, useful in the treatment of atherosclerosis are disclosed.

  N-酰基四氢异喹啉包括以下化合物的新型化合物，其化学式为##STR1##其中R.sup.1是C10-C25烷基链；一个取代的C10-C25烷基链；一个中断的C10-C25烷基链；一个取代的中断的C10-C25烷基链；二苯胺基；二-(R.sup.2-取代苯基)胺基；二-(杂环基)胺基；二-R.sup.2-取代的杂环基)胺基；二苯甲基；或二-(R.sup.2-取代苯基)甲基；R.sup.2是羟基，低烷基，低烷氧基，卤素，氨基，低烷基氨基或二-(低烷基)氨基；R.sup.3，R.sup.4和R.sup.5独立地是H或--(CH.sub.2 .sub.n --Ar；Ar是苯基，R.sup.2-取代苯基，杂环基或R.sup.2-取代杂环基；n=0,1或2；m=0,1或2；或其药学上可接受的盐，用于治疗动脉粥样硬化。
• N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A:
  申请人：Schering Corporation

  公开号：US05238935A1

  公开（公告）日：1993-08-24

  N-acyltetrahydroisoquinolines including novel compounds of the formula ##STR1## wherein R.sup.1 is a C10-C25 alkyl chain; a substituted C10-C25 alkyl chain; an interrupted C10-C25 alkyl chain; a substituted interrupted C10-C25 alkyl chain; diphenylamino; di-(R.sup.2 -substituted phenyl)amino; di-(heteroaryl)amino; di-(R.sup.2 -substituted heteroaryl)amino; diphenylmethyl; or di-(R.sup.2 -substituted phenyl)methyl; R.sup.2 is hydroxy, lower alkyl, lower alkoxy, halogeno, amino, lower alkylamino or di-(lower alkyl)amino; R.sup.3, R.sup.4 and R.sup.5 are independently H or --(CH.sub.2).sub.n --Ar; Ar is phenyl, R.sup.2 -substituted phenyl, heteroaryl or R.sup.2 - substituted heteroaryl; n=0,1 or 2; m=0,1 or 2; or a pharmaceutically acceptable salt thereof, useful in the treatment of atherosclerosis are disclosed.

  公开了用于动脉粥样硬化治疗的N-酰基四氢异喹啉化合物，包括具有以下式子的新化合物：##STR1##其中R.sup.1是C10-C25烷基链; 取代的C10-C25烷基链; 中断的C10-C25烷基链; 取代的中断的C10-C25烷基链; 二苯胺基; 二-(R.sup.2-取代苯基)氨基; 二-(杂环)氨基; 二-(R.sup.2-取代杂环)氨基; 二苯甲基; 或二-(R.sup.2-取代苯基)甲基; R.sup.2是羟基，低烷基，低烷氧基，卤素，氨基，低烷基氨基或二-(低烷基)氨基; R.sup.3，R.sup.4和R.sup.5独立地是H或--(CH.sub.2).sub.n --Ar; Ar是苯基，R.sup.2-取代苯基，杂环或R.sup.2-取代杂环; n=0,1或2; m=0,1或2; 或其药学上可接受的盐。
• N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
  申请人：SCHERING CORPORATION

  公开号：EP0514851A1

  公开（公告）日：1992-11-25

  N-acyltetrahydroisoquinolines including novel compounds of the formula    wherein R¹ is a C10-C25 alkyl chain; a substituted C10-C25 alkyl chain; an interrupted C10-C25 alkyl chain; a substituted interrupted C10-C25 alkyl chain; diphenylamino; di-(R²-substituted phenyl)amino; di-(heteroaryl)amino; di-(R²-substituted heteroaryl)amino; diphenylmethyl; or di-(R²-substituted phenyl)methyl;    R² is hydroxy, lower alkyl, lower alkoxy, halogeno, amino, lower alkylamino or di-(lower alkyl)amino;    R³, R⁴ and R⁵ are independently H or -(CH₂)n-Ar;    Ar is phenyl, R²-substituted phenyl, heteroaryl or R²-substituted heteroaryl;    n= 0,1 or 2;    m= 0,1 or 2; or a pharmaceutically acceptable salt thereof, useful in the treatment of atherosclerosis are disclosed.

  N-酰基四氢异喹啉，包括式中的新型化合物 其中 R¹ 是 C10-C25 烷基链；取代的 C10-C25 烷基链；间断的 C10-C25 烷基链；取代的间断的 C10-C25 烷基链；二苯基氨基；二-(R²-取代的苯基)氨基；二-(杂芳基)氨基；二-(R²-取代的杂芳基)氨基；二苯基甲基；或二-(R²-取代的苯基)甲基； R² 是羟基、低级烷基、低级烷氧基、卤素、氨基、低级烷基氨基或二-(低级烷基)氨基； R³、R⁴ 和 R⁵ 独立地为 H 或-(CH₂)n-Ar； Ar 是苯基、R²-取代的苯基、杂芳基或 R² 取代的杂芳基； n= 0、1 或 2； m= 0、1 或 2； 或其药学上可接受的盐，用于治疗动脉粥样硬化。
• MOLLLOV N. M.; BEHKOB A. P., NAUCH. TR. PLOVDIV. YH-T. XIMIYA, 1978(1979), 16, HO 3, 191-214
  作者：MOLLLOV N. M.、 BEHKOB A. P.

  DOI：——

  日期：——
• US5124337A
  申请人：——

  公开号：US5124337A

  公开（公告）日：1992-06-23